Revisiting the links between glycaemia, diabetes and cardiovascular disease

Diabetologia

Volumn 56, Issue 4, 2013, Pages 686-695

  Sattar, N ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular risk; Glucose; HbA1c; Linearity; Meta analysis; Review; Statins; Triacylglycerol

Indexed keywords

ANTIDIABETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DISEASE DURATION; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SYSTEMATIC REVIEW (TOPIC);

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERGLYCEMIA; MALE; META-ANALYSIS AS TOPIC; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 84876470858     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2817-5     Document Type: Review

References (48)

1. Freeman DJ, Norrie J, Caslake MJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51:1596-1600
2. Preiss D, Welsh P, Murray HM et al (2010) Fasting plasma glucose in non-diabetic participants and the risk for incident cardiovascular events, diabetes, and mortality: results from WOSCOPS 15-year follow-up. Eur Heart J 31:1230-1236
3. Emerging Risk Factors Collaboration, Sarwar N, Gao P et al (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222
4. Sarwar N, Aspelund T, Eiriksdottir G, et al (2010) Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med 7:e1000278
5. Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209-1216
6. Selvin E, Steffes MW, Zhu H et al (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med 362:800-811
7. 1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia 56:92-100
8. Hippisley-Cox J, Coupland C, Vinogradova Y et al (2008) Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 336:1475-1482
9. Wannamethee SG, Papacosta O, Whincup PH et al (2011) The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. Diabet Med 28:23-30
10. NICE (2012) Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. NICE public health guidance 38. Available from www.nice.org.uk/nicemedia/live/13791/59951/59951.pdf. Accessed 3 Jan 2013
11. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234
12. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N (2011) Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 171:404-410
13. Evans JM, Wang J, Morris AD (2002) Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 324:939-942
14. Preiss D, Sattar N, McMurray JJ (2011) A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J 161:210-219
15. Tonelli M, Muntner P, Lloyd A et al (2012) Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380:807-814
16. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
17. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR (2008) Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565-1576
18. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559
19. The ADVANCE Collaborative Group (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572
20. Duckworth W, Abraira C, Moritz T et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139
21. Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765-1772
22. Control Group, Turnbull FM, Abraira C et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288-2298
23. Yudkin JS, Richter B (2009) Intensive glucose control and cardiovascular outcomes. Lancet 374:522
24. Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591
25. 1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 55:636-643
26. ORIGIN Trial Investigators, Gerstein HC, Bosch J et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319-328
27. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N et al (2009) Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302:1993-2000
28. Goldfine AB, Kaul S, Hiatt WR (2011) Fibrates in the treatment of dyslipidemias - time for a reassessment. N Engl J Med 365:481-484
29. Sattar N (2008) Why metabolic syndrome criteria have not made prime time: a view from the clinic. Int J Obes (Lond) 32(Suppl 2):S30-S34
30. Ghouri N, Preiss D, Sattar N (2010) Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 52:1156-1161
31. Sattar N, McConnachie A, Shaper AG et al (2008) Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371:1927-1935
32. Simmons RK, Alberti KG, Gale EA et al (2010) The metabolic syndrome: useful concept or clinical tool? Report of a WHO Expert Consultation. Diabetologia 53:600-605
33. Preiss D, Tikkanen MJ, Welsh P et al (2012) Lipid-modifying therapies and risk of pancreatitis. A meta-analysis. JAMA 304:804-811
34. Wannamethee SG, Papacosta O, Lawlor DA et al (2012) Do women exhibit greater differences in established and novel risk factors between diabetes and non-diabetes than men? The British Regional Heart Study and British Women's Heart Health Study. Diabetologia 55:80-87
35. Logue J, Walker JJ, Colhoun HM et al (2011) Do men develop type 2 diabetes at lower body mass indices than women? Diabetologia 54:3003-3006
36. Sourij H, Holman RR (2012) Women develop diabetes at higher BMIs than men. Diabetologia 55:855-856
37. Paul S, Thomas G, Majeed A, Khunti K, Klein K (2012) Women develop type 2 diabetes at a higher body mass index than men. Diabetologia 55:1556-1557
38. Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362
39. Ridker PM, Danielson E, Fonseca FA et al (2008) Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359:2195-2207
40. Sattar N, Preiss D, Murray HM et al (2010) Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 375:735-742
41. Preiss D, Seshasai SR, Welsh P et al (2011) Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 305:2556-2564
42. Preiss D, Khunti K, Sattar N (2011) Combined cardiovascular and diabetes risk assessment in primary care. Diabet Med 28:19-22
43. Emerging Risk Factors Collaboration, Seshasai SR, Kaptoge S et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364:829-841
44. Gregg EW, Cheng YJ, Saydah S et al (2012) Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care 35:1252-1257
45. Ford ES (2011) Trends in the risk for coronary heart disease among adults with diagnosed diabetes in the U.S.: findings from the National Health and Nutrition Examination Survey, 1999-2008. Diabetes Care 34:1337-1343
46. Harron KL, Feltbower RG, McKinney PA, Bodansky HJ, Campbell FM, Parslow RC (2011) Rising rates of all types of diabetes in south Asian and non-south Asian children and young people aged 0-29 years in West Yorkshire, UK, 1991-2006. Diabetes Care 34:652-654
47. Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053
48. Looker HC, Nyangoma SO, Cromie D et al (2012) Diabetic retinopathy at diagnosis of type 2 diabetes in Scotland. Diabetologia 55:2335-2342